Hepion pharmaceuticals, inc. (CTRV)
CashFlow / TTM
Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13
Cash flows from operating activities:
Net loss

-6,718

-7,396

-5,734

-8,742

-9,449

0

0

0

-15,848

-14,891

-22,147

-18,446

-16,971

-16,998

-17,167

-17,647

-17,721

-14,347

0

0

0

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

66

-146

-101

34

234

0

0

0

1,646

1,756

1,911

1,585

1,392

901

1,402

1,852

2,017

2,118

0

0

0

-

-

-

-

Change in fair value of derivative instrument-warrants

-398

-1,345

-5,187

-5,123

-5,322

0

0

0

-4,348

-4,314

0

0

0

-

-

-

-

387

0

0

0

-

-

-

-

Change in fair value of contingent consideration

-160

270

475

605

265

0

0

0

114

90

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in the fair value of debt

179

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount recorded as interest expense

486

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred taxes adjustment

-

-

-

-

-536

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss on the sale of fixed assets

-

-

-

-

-4

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense on note payable to parent

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Depreciation and amortization expense

26

24

22

18

18

0

0

0

26

27

26

23

23

21

21

20

18

16

0

0

0

-

-

-

-

Changes in operating assets and liabilities:
Accounts payable and accrued expense

-424

-178

-2,145

-1,089

-897

0

0

0

-2,202

-2,128

-1,815

-536

947

3,135

2,672

3,282

3,819

1,516

0

0

0

-

-

-

-

Deferred rent liability

-

-

-

-

-9

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable, accrued expenses and due to Synergy

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Prepaid expenses and other assets

330

197

102

79

82

0

0

0

-433

-287

-251

-381

-346

-191

209

507

766

563

0

0

0

-

-

-

-

Net cash used in operating activities

-7,565

-10,217

-11,958

-14,112

-15,646

0

0

0

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Total Adjustments

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,434

6,003

4,278

3,917

0

0

0

Net Cash used in Operating Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-16,499

-15,484

-11,432

-9,672

-6,025

-3,501

-2,290

-1,363

0

0

0

Cash flows from investing activities:
Proceeds from sale of fixed assets

-

-

-

-

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchase of property and equipment

51

0

0

0

-

-

-

-

-

-

-

-

-

6

6

35

46

83

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

-51

-45

-45

-37

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net Cash Used in Investing Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6

-35

-46

-83

0

0

0

-

-

-

-

Cash flows from financing activities:
Change in current portion of capital lease

-

-

-

-

-

-

-

-

-

10

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the issuance of common stock

-

-

-

-

1,635

0

0

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of short term debt and common stock

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the exercise of warrants

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from stock options exercised

-

-

-

-

-

-

-

-

-

31

31

27

2

34

0

0

0

-

-

-

-

-

-

-

-

Repayment of debt financing

1,250

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

18,707

16,094

26,572

11,834

12,523

0

0

0

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Borrowings under demand note payable to Synergy

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net Cash provided by Financing Activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

3,109

0

0

0

Net decrease in cash

-

-

-

-2,315

-

-

-

0

5,750

5,578

180

719

1,237

2,840

0

0

0

-

-

-

-

-

-

-

-

Supplementary disclosure of cash flow information:
Cash paid for interest

26

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

6,391

8,788

659

1,731

0

0

0

Supplementary disclosure of non-cash financing activities:
Stock issued to employees in lieu of cash payment for accrued bonus

-

-

-

-

296

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock issued to employees in lieu of cash payment for accrued bonuses

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of convertible preferred stock

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accretion of Series C, D and E Preferred stock discount upon conversion

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of common stock for debt redemption

500

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Adoption of Lease accounting

773

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series C
Conversion of convertible preferred stock

147

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-